NSAID use and abuse in gastroenterology: Refractory peptic ulcers

Acta Gastro-Enterologica Belgica

Volumn 62, Issue 4, 1999, Pages 418-420

  Lanas, A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Aspirin; Gastric secretion; Helicobacter pylori; NSAID; Paracetamol; Peptic ulcers; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTON PUMP INHIBITOR;

CIGARETTE SMOKING; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DRUG MISUSE; DRUG UTILIZATION; GASTROINTESTINAL SURGERY; GENETIC SUSCEPTIBILITY; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; RISK FACTOR; STOMACH ACID SECRETION; TREATMENT INDICATION; ULCEROGENESIS; ZOLLINGER ELLISON SYNDROME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; RECURRENCE;

EID: 0033393660     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. LANAS A., REMACHA B., ESTEVA F., SÁINZ R. Risk factors associated with refractory peptic ulcers. Gastroenterology, 1995, 109 : 1124-1133.
2. WILDER-SMITH C.H., ERNST T., GENNONI M., ZEYEN B., HALTER F., MERKI H.S. Tolerance to oral H2-receptor antagonists. Dig. Dis. Sci., 1990, 35 : 976.
3. ANDERSSON T., CEDEBERG C., EDVARDSSON G., HEGGELUND A., LUNDBORG P. Effect of omeprazole treatment on diazepan plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther., 1990, 47 : 79.
4. ARMSTRONG D., ARNOLD R., CLASSEN M., FISCHER M., GOEBELL H., BLUM A.L., the RUDER study group. Prospective multicentre study of risk factors associated with delayed healing of recurrent duodenal ulcers (RUDER). Gut, 1993, 34: 1319-1326.
5. COLLEN M.J., STANCZAK V.J., CIARLEGLIO C.A. Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication). Dig. Dis. Sci., 1989, 34 (2) : 233-237.
6. LANAS A., HIRSCHOWITZ B.I. Influence of smoking on basal and on basal and on vagally and maximally stimulated gastric acid and pepsin secretion. Scand. J. Gastroenterol., 1992, 27 : 208-212.
7. KATSCHINSKI B.D., GOEBELL H., ARNOLD R., CLASSEN M., FISHER M., WITZEL L., BLUM A.L. Smoking as a risk factor for slow duodenal ulcer healing. Eur. J. Gastroenterol. Hepatol., 1991, 3 : 443-7.
8. BARDHAN K.D. Refractory duodenal ulcer. Gut, 1984, 25: 714-717.
9. KIRKPATRICK P.M., HIRSCHOWITZ B.J. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion. Gastroenterology, 1980, 79 : 4-10.
10. LANAS A. Symposium : New approaches to management of NSAID toxicity : Resistant ulcers. Gut, 1997, 41 (suppl 3) : A7.
11. HIRSCHOWITZ B.I., LANAS A. NSAID association with gastrointestinal bleeding and peptic ulcer. Agents and Actions, 1991, 35 (suppl) : 93-101.
12. PERRAULT J., FLEMING C.R., DOZOIS R.R. Surreptitious use of salicylates : a cause of chronic recurrent gastroduodenal ulcers. Mayo Clin. Proc., 1988, 63 : 337-342.
13. HIRSCHOWITZ B.I., LANAS A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology, 1998, 114 : 883-892.
14. HAWKEY C.J., KARRASCH J.A., SZCZEPAÑSKI L., WALKER D.G., BARKUN A., SWANNELL A.J., YEOMANS N.D. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 1998, 338 : 727-734.
15. YEOMANS N., TULASSAY Z., JUHASZ L., RACZ I., HOWARD J.M., REBSBURG C.J., SWANNELL A.J. HAWKEY C.J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 1998, 338 : 716-726
16. HAWKEY C.J., TULLASAY Z., SZCZAPANSKI L., VAN RENSENBURG C.J., FILIPOWICZ A., LANAS A., WASON C.M., PEACOCK R.A., GILLON K.R.W. Helicobacter pylori eradication in patients taking non-steroidal antiinflammatory drugs : The HELP NSAIDS Study. Lancet. 1998, 352 (2): 1016-21.
17. LANAS A., HAGGERTY P., HIRSCHOWITZ B.I. In vitro studies of anti-inflammatory agents and prostaglandins E2 on stimulated normal human fibroblast growth. Implication for ulcer healing. Inflammo Pharmacol., 1994, 2 : 377-387.
18. BAYER B.M., BEAVEN M.N. Evidence that indomethacin reversibly inhibits cell growth in the G1 phase of the cell cycle. Biochem. Pharmacol., 1979, 28: 441-443.
19. GAULT M.H., RUDWAL T.C., REDMOND N.I. Analgesic habits of 500 veterans : Incidence and complications of abuse. Can. Med. Assoc. J., 1968, 98: 619-626.
20. JYOTHEESWARAN S., SHAH A.N., JIN H.O., POTTER G.D., ONA F.V., CHEY W.Y. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY : is empirical triple therapy justified ? Am. J. Gastroenterol., 1998 Apr., 93 (4) : 574-8.
21. HIRSCHOWITZ B.I., MOHNEN J., SHAW S. High recurrence rate of duodenal ulcer despite H. pylori eradication in a clinical subset - rapidiy recurrent peptic ulceration. Gastroenterology, 1994, 106 : A94.
22. LEIVONEN M.K., HAGLUND C.H., NORDLING S.F. Helicobacter pylori infection after partial gastrectomy for peptic ulcer and its role in relapsing disease. Eur. J. Gastroenterol. Hepatol., 1997, 9 (4): 371-374.
23. JORDAN P.H., THORNBY J. Twenty years after parietal cell vagotomy or selectivevagotomy-antrectomy for treatment of duodenal ulcer. Ann. Surg., 1994, 220 : 283-296.